drugset

drugset / Trial / NCT02197897

Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors

NCT02197897 ↗

Phase 2 Completed 15 enrolled Baylor College of Medicine National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

Evaluate the treatment of tamoxifen of low/intermediate-risk bladder tumors

Timeline

Start: 2015-04-01
Primary completion: 2017-09-12
Completion: 2019-06-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tamoxifen	Small molecule	20 mg	Oral

Indications